NASDAQ:KRYS Krystal Biotech (KRYS) Stock Price, News & Analysis $299.45 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$304.00 +4.55 (+1.52%) As of 05/22/2026 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Krystal Biotech Stock (NASDAQ:KRYS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Krystal Biotech alerts:Sign Up Key Stats Today's Range$297.18▼$309.4150-Day Range$245.39▼$316.3052-Week Range$122.80▼$319.48Volume162,215 shsAverage Volume316,855 shsMarket Capitalization$8.83 billionP/E Ratio40.03Dividend YieldN/APrice Target$324.11Consensus RatingModerate Buy Company Overview Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments. The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition. KB103 has advanced through clinical trials under orphan drug and breakthrough therapy designations granted by the U.S. Food and Drug Administration. In addition to DEB, Krystal Biotech is advancing a second program, KB105, aimed at correcting the genetic defect underlying pseudoxanthoma elasticum. The company maintains an in-house cGMP manufacturing facility to support both development activities and future commercialization efforts. Since its initial public offering on the Nasdaq in July 2019, Krystal Biotech has expanded its clinical and regulatory footprint, enrolling patients in multiple U.S. and international study sites. The company is led by a management team with deep expertise in gene therapy development and regulatory strategy. With a growing pipeline and a dedicated manufacturing infrastructure, Krystal Biotech is positioned to advance its targeted gene therapies through late-stage development and toward potential approval.AI Generated. May Contain Errors. Read More Krystal Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreKRYS MarketRank™: Krystal Biotech scored higher than 61% of companies evaluated by MarketBeat, and ranked 264th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingModerate Buy Consensus RatingKrystal Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 10 buy ratings, 2 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Krystal Biotech is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageKrystal Biotech has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Krystal Biotech's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth31.83% Earnings GrowthEarnings for Krystal Biotech are expected to grow by 31.83% in the coming year, from $7.98 to $10.52 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Krystal Biotech is 40.03, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.03.Price to Earnings Ratio vs. SectorThe P/E ratio of Krystal Biotech is 40.03, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.00.Price to Book Value per Share RatioKrystal Biotech has a P/B Ratio of 6.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Krystal Biotech's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.08% of the float of Krystal Biotech has been sold short.Short Interest Ratio / Days to CoverKrystal Biotech has a short interest ratio ("days to cover") of 13.76, which indicates bearish sentiment.Change versus previous monthShort interest in Krystal Biotech has recently increased by 6.29%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKrystal Biotech does not currently pay a dividend.Dividend GrowthKrystal Biotech does not have a long track record of dividend growth. News and Social Media4.4 / 5News Sentiment0.98 News SentimentKrystal Biotech has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Krystal Biotech this week, compared to 5 articles on an average week.Search Interest24 people have searched for KRYS on MarketBeat in the last 30 days. This is an increase of 1,100% compared to the previous 30 days.MarketBeat Follows8 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,359,891.00 in company stock.Percentage Held by Insiders13.10% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.29% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Krystal Biotech's insider trading history. Receive KRYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KRYS Stock News HeadlinesCorbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference CallMay 21, 2026 | globenewswire.comKrystal Biotech gains regulatory approval to sell gene therapy in the United KingdomMay 19, 2026 | bizjournals.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.May 25 at 1:00 AM | Weiss Ratings (Ad)Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis BullosaMay 18, 2026 | globenewswire.comKrystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 16, 2026 | americanbankingnews.comKrystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comThis Profitable Biotech Stealthily Climbs Into A Buy ZoneMay 11, 2026 | investors.comKrystal Biotech (KRYS) Is Up 6.5% After Vyjuvek-Fueled Q1 Profit Jump And Investor Conference UpdateMay 11, 2026 | finance.yahoo.comSee More Headlines KRYS Stock Analysis - Frequently Asked Questions How have KRYS shares performed this year? Krystal Biotech's stock was trading at $246.54 at the beginning of 2026. Since then, KRYS shares have increased by 21.5% and is now trading at $299.45. How were Krystal Biotech's earnings last quarter? Krystal Biotech, Inc. (NASDAQ:KRYS) posted its quarterly earnings data on Monday, May, 4th. The company reported $1.83 earnings per share for the quarter, topping analysts' consensus estimates of $1.45 by $0.38. The firm earned $116.36 million during the quarter, compared to analysts' expectations of $112.11 million. Krystal Biotech had a trailing twelve-month return on equity of 19.25% and a net margin of 53.92%. Read the conference call transcript. When did Krystal Biotech IPO? Krystal Biotech (KRYS) raised $40 million in an IPO on Wednesday, September 20th 2017. The company issued 3,960,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO. Who are Krystal Biotech's major shareholders? Krystal Biotech's top institutional shareholders include Redmile Group LLC (2.28%), Dimensional Fund Advisors LP (1.59%), First Trust Advisors LP (1.19%) and Janus Henderson Group PLC (0.90%). Insiders that own company stock include Suma Krishnan, Dino A Rossi, Daniel Janney, Kathryn Romano, Andrew C Orth and Julian S Gangolli. View institutional ownership trends. How do I buy shares of Krystal Biotech? Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Krystal Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Krystal Biotech investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings5/04/2026Today5/25/2026Next Earnings (Estimated)8/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 KRYS's financial health is in the Green zone, according to TradeSmith. KRYS has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KRYS CIK1711279 Webwww.krystalbio.com Phone(412) 586-5830FaxN/AEmployees210Year Founded2017Price Target and Rating Average Price Target for Krystal Biotech$324.11 High Price Target$378.00 Low Price Target$284.00 Potential Upside/Downside+8.2%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)$7.48 Trailing P/E Ratio40.03 Forward P/E Ratio37.53 P/E GrowthN/ANet Income$204.83 million Net Margins53.92% Pretax Margin49.68% Return on Equity19.25% Return on Assets17.62% Debt Debt-to-Equity RatioN/A Current Ratio9.46 Quick Ratio9.06 Sales & Book Value Annual Sales$389.13 million Price / Sales22.69 Cash Flow$7.29 per share Price / Cash Flow41.08 Book Value$43.31 per share Price / Book6.91Miscellaneous Outstanding Shares29,480,000Free Float25,618,000Market Cap$8.83 billion OptionableOptionable Beta0.50 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:KRYS) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Krystal Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
